Home
Resources
Diseases
Training
SYSVAC
About
Registry
E-learning courses
News
Events
Network
Vision and Mission
Steering Committee
Map
Meetings
Join us
Home
Resources
Resources
Selected
COVID-19
Meningococcal disease
2021
Africa
Americas
Clear all
Type of publications
NITAG documentation
(77)
Systematic reviews (SYSVAC)
(5)
Topics
Available to download in languages
Regions
Africa
(17)
Americas
(65)
Europe
(76)
South-East Asia
(2)
Western Pacific
(14)
Countries
Argentina
(1)
Bolivia
(2)
Burkina Faso
(1)
Canada
(16)
Chile
(9)
Nigeria
(1)
Senegal
(2)
Uganda
(12)
United States of America
(37)
Diseases
COVID-19
(81)
Meningococcal disease
(1)
Ebola
(1)
Hepatitis B
(1)
HIV / AIDS
(1)
Human papillomavirus (HPV)
(6)
Malaria
(1)
Poliomyelitis
(2)
Rotavirus
(5)
Tetanus
(2)
Vaccine topics
Acceptance
(2)
Coverage
(1)
Ethical issues
(2)
Safety
(1)
Target population
Adults
(3)
All age groups
(3)
Children
(3)
Healthcare workers
(1)
Older adults
(1)
Parents/caregivers
(1)
Pregnant women
(5)
Publication date
2021
(82)
2024
(1)
2023
(20)
2022
(63)
2020
(64)
2019
(8)
2018
(4)
2017
(1)
2016
(10)
2015
(8)
2014
(6)
2013
(4)
2012
(1)
2011
(7)
2010
(1)
2009
(3)
2008
(1)
2007
(3)
2006
(3)
2005
(1)
1997
(1)
1993
(1)
1991
(1)
82 results found
2021
∙
UNITAG
Interim Advisory on the introduction of COVID-19 vaccine booster doses in Uganda
2021
∙
NACI
Interim guidance on booster COVID-19 vaccine doses in Canada
2021
∙
ACIP
Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5–11 Years
2021
∙
ACIP
Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines
2021
Interim Recommendations on the Use of COVID-19 Vaccines in Nigeria
2021
∙
Sara Oliver, ACIP
Janssen COVID-19 Vaccine - ACIP conclusion
2021
∙
ACIP
Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Janssen COVID-19 Vaccine
2021
∙
NACI
NACI has updated its recommendations on the use of COVID-19 vaccines to include advice on the use of the Janssen COVID-19 vaccine - May 3, 2021
2021
∙
NACI
NACI issues updated recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age - 27 August, 2021
2021
∙
NACI
NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series - 10 September, 2021
Home
Resources
Diseases
Training
SYSVAC
News
Events
Network
Sign in / Register